About IV All-Russian GMP Conference
To the attention of specialists in the pharmaceutical industry, industry, etc. specialists involved in ensuring the quality of medicines.
Good manufacturing practice is not a dogma, but a live experience of the industry, therefore, on September 23-25, 2019, the 4th All-Russian GMP conference with international participation in Svetlogorsk, Kaliningrad Region, Russia, in the multifunctional cultural center “Amber Hall” was held on the Baltic Sea .
The conference was attended by experts and representatives of regulatory bodies of various countries of the near and far abroad, including Mexico, Cuba, India, Japan, Spain, Harvatia, Hungary, Germany, EAEU countries.
- Experts in the pharmaceutical industry, representatives of state bodies, and leaders of relevant associations met at the 4th conference “Russia and the World. Managing the growth potential of the pharmaceutical market. ”
In the framework of this conference, issues such as:
- Effective government support measures
- Changes in legislation
- Actual issues of drug quality assessment
- Tools for the development of pharmaceutical industries
- Rules and procedures for conducting GMP inspections
- Export potential
- Organization of pharmacovigilance systems
- System of education and personnel potential, and much more.
During the conference, presentations were made by representatives of professional associations and communities, production specialists, experts in the field of professional development and qualifications of the pharmaceutical industry. And also, the presentation of Professor Tillayeva G.U. was presented.
Representatives of the Russian GMP inspectorate showed the most significant problems encountered by manufacturers of pharmaceuticals and pharmaceutical substances in both Russian and foreign countries when they pass the inspection for compliance with GMP standards.
Within the framework of this conference held in Svetlogorsk, a panel discussion was organized “The Single Market of the EAEU Countries: Export and Prospects for Interaction”, at which representatives of the regulatory authorities of Russia, Belarus, Armenia, Kazakhstan and others shared their experiences.
The speakers discussed the regulation of the circulation of medicines in the EAEU Countries and the mutual recognition procedures, issues of the Pharmacopoeia of the Union and especially the transition from national legislative norms to common requirements.
General Director of Federal Government Budgetary Institution “Scientific Centre for Expert Evaluation of Medicinal Products” of Ministry of Health of the Russian Federation Yuriy Olefir noted in an appeal to pharmaceutical manufacturers and holders of registration cards that drugs with national registration that did not formalize the procedure for bringing the drug registration dossier in accordance with the requirements of the Union will leave the market on January 1, 2026. This procedure is generally formal clause.
Department of SQMM
